According to the Zhitong Finance App, Conoa-B (02162) announced that the company's product Kangyueda® (IL-4Rα monoclonal antibody, sipqibizumab) achieved total revenue of about RMB 660 million in the first three quarters of 2026, an increase of about 227% over the previous year. The core drive came from actual market demand and a sharp increase in the number of admitted hospitals. Thanks to national policy support, Kangyueda® has been approved for marketing in adults since January 1, 2026 for the three indications of severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwnP), and seasonal allergic rhinitis (SAR), and two types of vials and pre-filled automatic pens The packages have all been included in China's national medical insurance drug catalogue. The medical insurance payment standard is RMB 1,039 per bottle (specification is 300 mg/2 ml), which greatly enhances affordability for Chinese patients. Meanwhile, in July 2026, Kangyueda® was officially included in the “National Essential Drug Catalogue (2026 Edition)”, which will take effect from September 1, 2026. According to the relevant regulations on basic drugs, public medical institutions at all levels across the country must equip and prioritize the use of drugs in the catalogue as required, further broaden terminal prescription scenarios, and enhance drug accessibility.
As of September 30, 2026, the commercialization team has reached more than 550 people, and the market access work is progressing rapidly. It has covered 30 provinces and nearly 290 cities, covered more than 2,200 hospitals, continued to produce about 2,200 hospitals, more than 1,300 hospitals with in-hospital medication, established stable cooperative relationships with nearly 60 first-level dealers, and has set up nearly 700 pharmacies.
China's National Drug Administration (NMPA) has recently approved the marketing application for new indications of sipcibalimab (anti-IL-4Rα monoclonal antibody, trade name: Kang Yueda, R&D code: CM310) for the treatment of moderate to severe atopic dermatitis (AD) in adolescents. Both packaging of the Xillin bottle (300mg [2ml] /bottle) and the prefilled autoinjector pen (300mg [2ml]/stick) were approved.
The approval for marketing of spoximab was based on a randomized, double-blind, placebo-controlled phase III clinical study of the efficacy and safety of 180 young patients aged 12 years <18. The study results showed that in the 18th week of treatment, up to 73.9% of patients achieved an EASI-75 response, which was significantly higher than that of the placebo group (43.3%, P<0.0001). Up to 57.1% of patients achieved IGA response, which was significantly superior to the placebo group (25.0%, P<0.0001). In addition, PP-NRS improved by 49.5% compared to baseline for patients in the spiqibizumab group. In terms of safety, the incidence of adverse events (TEAEs) during treatment was comparable to that of the placebo group, and mostly mild to moderate. Furthermore, compared with the results of the adult study, the safety of young adults with moderate to severe AD was good, and no new safety signals were found.